Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Bristol Myers Squibb and Ipsen Biopharmaceuticals, Inc.

Advances In™ Pancreatic Cancer: Expert Recommendations on Treating Metastatic Disease

Release Date: September 29, 2020
Expiration Date: September 29, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of pancreatic ductal adenocarcinoma (PDAC), with a forward-looking perspective on how new and novel agents might impact clinical practice. Current and emerging treatment strategies for metastatic and resectable PDAC, supporting clinical trial data, the evolving role of mutational testing, and investigational approaches will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Ipsen Biopharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of pancreatic cancer. This activity will provide education to a broad multidisciplinary team who are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe mechanisms by which compounds for pancreatic cancer treatment exert their activity, as well as developments to improve their delivery
  • Discuss recent clinical trial data regarding the efficacy and safety of evolving treatment strategies for metastatic pancreatic cancer
  • Explain how recent evidence is impacting treatment paradigms in the management of metastatic pancreatic cancer
  • Identify treatment-related toxicities from recent clinical trials and methods to mitigate their impact on clinical outcomes among patients with metastatic pancreatic cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Johanna Bendell, MD
Johanna Bendell, MD
Chief Development Officer
Director, GI Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Johanna Bendell, MD, has no relevant financial relationships with commercial interest to disclose.

Tanios Bekaii-Saab, MD, FACP
Tanios Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Leader, Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Chair, ACCRU Research Consortium
Phoenix, AZ

Disclosures: Research Funding (to institution): AbGenomics Holdings, Amgen, Array BioPharma, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis Oncology, Eli Lilly, Genentech, Incyte Corporation, Ipsen Biopharmaceuticals, Merck, Seattle Genetics; Consulting (to institution): Array BioPharma, Bayer, Genentech, Incyte Corporation, Ipsen Biopharmaceuticals, Merck, Seattle Genetics; Consulting (to self): Boehringer Ingelheim, Daiichi Sankyo, Eisai, Janssen Pharmaceuticals, Natera, Sobi, Treos Bio; IDMC/DSMB (to self): AstraZeneca, Exelixis, Eli Lilly, PanCAN, 1Globe Health Institute; Scientific Advisory Board: Imugene, Immuneering Corporation, Sun BioPharma; Other: Inventions/Patents: WO/2018/183488 and WO/2019/055687.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By